IL7 and neoplasm: The tumor specificity of the B16-LX/IL-7 vaccine was further confirmed in vivo, where the B16-LX/IL-7 vaccine controlled B16-F10 tumor growth but failed to inhibit EL-4 lymphoma tumors [28] (Fig. 3; Table 1).